Background-Heart failure with reduced ejection fraction (HFrEF) and obstructive sleep apnea
Introduction
Obstructive sleep apnea (OSA), present in approximately a third of all patients with heart failure (HF) with reduced ejection fraction (HFrEF), [1] [2] [3] is an independent predictor of mortality 4 .
Common to both HFrEF and OSA are sympathetic nervous system (SNS) activation and impaired myocardial energetic efficiency 4 .
Myocardial efficiency estimates the capacity of the heart to convert oxygen into effective forward stroke work [5] [6] [7] [8] [9] . The non-invasively derived cardiac work-metabolic index (WMI)
estimates efficiency by quantifying forward minute-work of the left ventricle (LV), corrected for the rate of oxidative metabolism measured using 11 C-acetate positron emission tomography (PET) [8] [9] [10] . Oxidative metabolism represents the utilization of substrates via the tricarboxylic acid cycle for the production of adenosine triphosphate and is directly linked to myocardial oxygen consumption 6, 8, 10 .
HFrEF is an energy-deplete state, in which increased metabolic oxidative demand exists at the expense of forward stroke work, which causes further reflex-mediated increases in efferent sympathetic discharge and norepinephrine (NE) release 11, 12 . In OSA, acute upper airway obstruction generates greater negative intra-thoracic pressure (i.e. increased afterload) and causes hypoxia, hypercapnia and arousal from sleep 4, 13 . These several stimuli increase simultaneously both metabolic demand and sympathetic discharge. Thus, during sleep these interactions between OSA and HFrEF will perturb the myocardial oxygen supply-demand ratio, impacting adversely LV performance 4, 9, [13] [14] [15] [16] [17] [18] .
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HFrEF patients with moderate to severe OSA, 1 month of CPAP improved daytime LV ejection fraction and arterial baroreflex modulation of heart rate and lowered heart rate, systolic blood pressure and sympathetic vasoconstrictor discharge directed at skeletal muscle [18] [19] [20] . However, the mechanism by which nocturnal CPAP improves daytime LV systolic function is presently unclear. If CPAP improved cardiac contractility but increased cardiac sympathetic drive and myocardial oxygen consumption, this would indicate reduced efficiency and could lead to detrimental consequences such as those induced by sympathomimetic inotropic therapies 21 . The present investigation was stimulated by our previous exploratory non-randomized study of 7
patients with OSA and HFrEF, in whom CPAP increased cardiac efficiency. Although consistent with an energy sparing effect, a definitive test of these concepts would require a larger cohort evaluated in a randomized controlled trial, accompanied by concurrent evaluation of myocardial SNS activity 9 . In patients with decreased LV function, reduced cardiac presynaptic nerve function, measured using myocardial retention of 11 C-hydroxyephedrine (HED) on PET 22, 23 or 123 I-MIBG washout imaging 24, 25 , has been shown to predict the severity of arrhythmias and adverse outcomes [26] [27] [28] [29] We therefore hypothesized that in patients with OSA and HFrEF, treatment of OSA by nocturnal CPAP for 6 to 8 weeks would increase daytime myocardial WMI, an estimate of efficiency, measured using 11 C-acetate and echocardiography, and at the same time improve presynaptic sympathetic neuron (SN) function, as quantified using 11 C-HED PET.
Methods

Study Design
The study was a single center, unblinded, randomized controlled trial with balanced consistent with an energy sparing effect, a definitive test of these concepts would ld d req eq e ui ui uire e re a a a l l lar ar a ge ger cohort evaluated in a randomized controlled trial, accompanied by concurrent evaluation of my my yo oc ocar ar ardi di dial al al S S SNS NS a a ac ct ctivity 9 . In patients with decr rea ea eas se ed LV function on n, re edu du duc ce ced cardiac presynaptic n nerv v ve e function n, me me meas su ur ured ed d u usi si ing n ng m m myo yo yoca ca ard d dial re retent tio o on o of of 1 11 11 C C C-h hy hyd dr ro ox xye yeph ph p ed edri ri rine n ne ( (HE HE HED) D) D) on n n PE PE PET T T randomization ratio (1:1). The trial was designed to determine the short-term (6-8 weeks) effects of CPAP on cardiac energetic and sympathetic nerve function in patients with OSA and HFrEF.
The study was approved by the University of Ottawa Heart Institute Human Research Ethics
Board. All patients provided informed consent.
Experimental Protocol
Forty-five patients with HFrEF and OSA were consecutively recruited with the following inclusion criteria: a) LV systolic dysfunction [left ventricular ejection fraction (LVEF) <45% by echocardiography, radionuclide or contrast ventriculography]; b) NYHA Class II dyspnea; c) stable condition with optimally tolerated medical therapy, unchanged for >4 weeks; d) OSA defined on nocturnal polysomnogram as an apnea/hypopnea index (AHI) >10 events/hr with a predominantly obstructive pattern (>80%). Exclusion criteria were patients with: a) unstable angina or myocardial infarction within 4 weeks prior to study enrollment; b) a requirement for revascularization; c) transmural scar known to be >25% of the LV on prior perfusion imaging; d)
severe valvular dysfunction; e) life expectancy <1 year from other co-morbidities; f) significant obstructive or restrictive lung disease; g) use of tricyclic antidepressants, cocaine or drugs which may alter catecholamine uptake; or hypnotic, benzodiazepine, SSRI, neuroleptic, narcotic or other medications which may alter sleep or sleep-disordered breathing; h) central sleep apnea; i) other primary sleep disorders; j) debilitating daytime somnolence.
Eligible and consenting patients were randomized and underwent baseline measurements including: clinical exam, electrocardiography (ECG), blood work, echocardiography, 11 C-acetate and 11 C-HED PET imaging.
Randomization
A stratified (by ischemic or non-ischemic etiology) block randomization scheme was used.
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Sleep Studies
Overnight polysomnogram was performed using the Alice system (Respironics, Murrysville, PA 
CPAP Titration and Therapy
Patients assigned to CPAP had a CPAP titration sleep study scheduled approximately 1-2 weeks after the baseline PET and echocardiography studies. Therapeutic CPAP pressure was A A An n ob b bst tru ru r ct ct ctiv iv ive ap ap a n ne nea a a wa wa was de de d fi fi fine ne ned d as as as c c ces s ssa sa ati tion on n o of f airflow for >1 >1 10 0 0 se se eco co cond nd ds s s wi wi ith th th p per er ers s sis iste te tent nt t r res es espi pi pira ra rato to t ry ry ry e e eff ff f or or rt t t as as as s s see ee een n n in n n t t the he he r r rib ib ibca ca c ge ge e o o or r r ab ab abdo d d men 
Echocardiography
Echocardiographic examinations were performed using an HP 5500 or ie33 ultrasound system equipped with a 2-to 4-MHz transducer (Philips, Andover, Massachusetts). LVEF was calculated using the bi-plane method of disks (modified Simpson's rule) 32 . Forward stroke volume (SV) was derived from the velocity-time integral of the pulsed Doppler LV outflow tract velocity signal and LV outflow tract diameter 33 . Stroke volume index (SVI) was derived by dividing the SV by the body surface area. Those performing the echocardiographic measurements (SYC, IGB) were blinded to patient clinical data and OSA status.
C-Acetate PET Protocol and Analysis
Immediately following echocardiography, patients were positioned supine in a quiet and awake state in the Siemens/CTI ECAT-ART PET (Knoxville, TN) or GE Discovery 690 PET/VCT (Waukesha, WI) scanner. A transmission scan was performed using isotope sources or x-ray CT to correct for photon attenuation 9 . Immediately following the transmission scan, 10-15mCi (370-550 MBq) 11 C acetate was administered intravenously and a 30-minute dynamic PET scan was initiated (10 frames x10 seconds; 2x30s; 5x100s; 3x180s, 2x300s) 9 .
Images were reconstructed using filtered-back-projection with a 12 mm Hann window of the ramp filter. Automatic reorientation of the images, and extraction of mean myocardial and cavity time-activity curves were performed using our FlowQuant© software [Ottawa, Canada] 34 .
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Assessment of myocardial efficiency
The 11 C-acetate clearance rate was combined with the stroke work data to estimate myocardial efficiency using the LV work metabolic index (WMI), as described previously: WMI = SVI × SBP × HR ÷ k mono ; where SVI is the stroke volume index determined by echocardiography, SBP is systolic blood pressure, HR is heart rate, and k mono is the mono-exponential rate constant for C-11 clearance from the myocardium [6] [7] [8] [9] . This equation is a modification of the minute-work-tooxygen consumption relationship originally defined as mechanical efficiency 5 .
C-HED PET Protocol and Analysis
11 C-HED was produced from 11 C-methyl iodide and metaraminol free base using standard methods in high purity and specific activity 35 . Two hours after 11 C-acetate injection (allowing for decay of 11 C: t 1/2 =20 min), the patient was repositioned in the scanner and underwent a transmission scan as noted above for attenuation correction followed by the administration of 10-15 mCi (370-550 MBq) of 11 C-HED and a 40 minute dynamic PET acquisition (10x10s;1x60s;5x100s;3x180s;4 x 300s) 36 .
Tracer retention rate (R (min -1 )) was used as an index of 11 C-HED uptake and calculated as: R = Myocardium Activity (t 30-40min ) ÷ Blood Activity (t 0-40min ) 27, 37 . The 11 C-HED data was also displayed using our standard retention polar map software, FlowQuant© [Ottawa, Canada] 38 .
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Sample size and Statistical Analysis
When designing the study, a sample size calculation was used which considered the estimates based on the best available evidence at the time (LV oxidative metabolism (k=0.046±0.009 min -1 ) and the WMI (6.1±1.7x10 6 mmHg ml/m 2 )) from data in our laboratory in patients with heart failure 7 .We calculated that a sample size of 40 patients (20 patients per group) would provide 80% power to detect a delta difference of 0.009 min -1 in oxidative metabolism or a delta difference of 1.53×10 6 mmHg ml/m 2 in the WMI for patients with CPAP using a two sample t- The change of continuous variables measured at baseline and after 6-8 weeks of CPAP or no-CPAP was compared between the two groups using Wilcoxon rank-sum tests. To include the patients with incomplete follow-up data, a repeated measure growth curve model which treated the within-group effect of time as a continuous variable, the treatment group (CPAP vs. no-CPAP) and an interaction term (treatment-time) as a fixed effect along with random intercept and slope was used to evaluate the effect of CPAP on myocardial energetics parameters from baseline to follow-up between treatment groups assuming that missing data is missing at random (MAR). The effects of treatment group, time and the interaction of treatment group and time were evaluated by F tests. The analysis was performed using PROC MIXED (SAS version 9.2).
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Th The e ch ch chan an nge ge ge o of f co co cont nt ntin in inuo uo uous us us var ar ria ia iab ble le les s me me eas as a ur ur ured ed ed a a at t ba ba base se seli li ine ne ne a a and nd nd a aft ft ter er er 6 6 6-8 -8 8 w w wee ee e ks ks ks o o of f f CP CP CPAP AP AP o o or r r no no no-CPAP was c c com om ompa pa pare re red d d be be betw tw wee ee een n n th th the e e tw tw wo o gr g grou ou oups ps ps u u us s sin in i g g g Wi Wi W lc lc lcox ox xon on on r ra ank-k-k-su su sum m m te te test sts s. To To To i i inc nc nclude the and treatment group to evaluate if the treatment effect of CPAP on the change of continuous variables was equal between different OSA severity groups. A subgroup analysis was performed for more severe OSA group (AHI>20) if a significant interaction was detected. Finally the linear regression was used to assess whether the OSA severity was correlated to the change in WMI and HED retention with CPAP in a subset of patients with automated confirmation of CPAP compliance. A p value of 0.05 was considered a statistically significant difference. The analysis was performed using SAS software (version 9.2, SAS Institute, Inc., Cary, North Carolina).
Results
The baseline demographics of the 45 study patients shown in Table 1 The baseline demographics of the 45 study patients shown in Table 1 indicate si sim mi mila la l r r characteristics of the two randomized groups (A: short-term CPAP therapy vs. B: No-CPAP)
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Effects of CPAP on LV parameters and Myocardial Energetics
There were no significant changes in any hemodynamic, LV or energetics parameters in the whole study population (Table 2, Figure 2A ). There appeared to be a positive directional change in the WMI in the CPAP arm compared to the non-CPAP arm, but this was not statistically significant by comparing the delta change (p= 0.574) and using a repeated measures growth curve model (p=0.417).
Pre-synaptic Sympathetic Nerve Function
The effect of CPAP therapy on pre-synaptic 11 C-retention in the whole study population is shown in Table 3 . In the CPAP-arm, one patient lacked baseline 11 C-HED data due to technical issues. Two patients who dropped out lacked follow-up 11 C-HED data. In the non-CPAP arm, two patients did not have follow-up 11 C-HED data: one who dropped out and another due to technical issues with tracer production. A significant increase in 11 C-HED retention occurred with the CPAP arm compared to the non-CPAP arm (p=0.003) (Table 3, Figure 3) . A significant increase in 11 C-HED retention in the CPAP arm was also found in the whole study population using a repeated measure growth curve mixed model (p=0.002).
The interaction analysis between CPAP and OSA severity with the change in 11 C-HED retention indicated that the beneficial effect of CPAP was independent from the OSA severity (p=0.892).
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Post-Hoc Analysis of Subgroup with severe OSA
Since the OSA severity was identified as an effect modifier to the treatment effect of CPAP on the change of SBP (p=0.016) and WMI (p=0.026) from the interaction analysis, a post-hoc analysis was applied to the subset of patients who had severe OSA (AHI >20 events/hour). Of these, 9 were randomized to CPAP and 16 were in the untreated group. There were no significant differences in any baseline parameters between the two groups ( Table 4) . CPAP therapy was accompanied by a significant increase in WMI (p=0.037) and SBP (p=0.024) ( Table 5 , Figure   2B ). The change of WMI and SBP remained significantly different between the two groups (p=0.010, 0.013, respectively) using a repeated measure growth curve mixed model, which included the patients with incomplete follow-up.
Correlations Between OSA Severity and Change in WMI and HED Retention with CPAP in Sub-set of Patients with Confirmation of CPAP Compliance
Sustained abolition of OSA would be anticipated in patients with automated verification of CPAP compliance 19 . In this group, there was a significant correlation between severity of OSA at baseline and subsequent changes in WMI (r=0.54, p=0.037, Figure 4 ), but not for concurrent changes in HED retention.
Discussion
In this randomized trial, we demonstrated a significant increase in 11 C-HED retention in those allocated to CPAP, indicating improved pre-synaptic SN function. We did not, however, demonstrate significant favorable alterations in myocardial function nor energetics in the treated group overall. Our findings suggest that short term CPAP therapy in patients with HFrEF and OSA improves myocardial sympathetic dysregulation, but not myocardial energetics.
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Impact of CPAP Therapy on Myocardial Energetics in Patients with HF and OSA
Heart failure has been described as an 'energy depleted state' 11, 12 . Drug therapies with energy sparing effects are associated with improved outcomes 11 , while those which improve performance at the expense of oxygen consumption often yield long-term detrimental effects 41,42 .
The metabolic and energetic effect of therapies such as CPAP is less well known.
In a hypothesis-generating pilot study of 7 non-randomized patients with HFrEF and OSA, we previously demonstrated an energetics benefit of 6 weeks of CPAP therapy, specifically, reduced myocardial oxidative metabolism and improved cardiac efficiency 9 . This led us to test our hypothesis in the current study, with a larger study population and a more rigorous randomized design. The primary outcome of the current study did not support this previous work. The current study was somewhat underpowered to detect significant differences given the small changes and larger standard deviations observed.
An improvement in LVEF with chronic CPAP therapy has been reported in some, but not all prior studies 15, 43 . We did not observe a statistically significant improvement in LVEF with CPAP vs. no-CPAP. One explanation is that the mean EF in the current study (LVEF 35.8 %±9.7) was not as severely depressed as it was in prior studies of patients with OSA and HF, in which LVEF averaged 25% 19, 39 . As such, the potential for improvement in LVEF in this cohort Patients entering this study had variable severity of OSA as defined by their AHI, with a small portion having more severe disease. As the detrimental cardiac impacts of OSA may be correlated with its severity, it is possible that the impact of therapy on the heart may vary with baseline OSA severity. In the small previous non-randomized pilot study, where CPAP was observed to improve energetics, most of the patients (5/7) had AHI >20. 9 The subgroup data in the current study is consistent with this previous work, suggesting that CPAP therapy might have benefit by improving energetics in patients with more severe OSA and HF, but given this was a post-hoc analysis definitive conclusions cannot be made. The findings support the need for further study.
Impact of CPAP Therapy on Myocardial SNS Activity in Patients with HF and OSA
CPAP therapy has been previously demonstrated to decrease fibular muscle SNS activity (MSNA) and improve HR variability in patients with HF and OSA 17, 44 . Impaired baroreflex sensitivity, also linked to excess SNS activity, in patients with HF and OSA improves with CPAP therapy 18 .
Previous studies involving patients with cardiomyopathy and sleep disordered breathing have identified increased myocardial sympathetic drive using semi-quantitative scintigraphic analysis of 123 I-MIBG washout rates 24, 25 . A recent non-randomized study suggested that adaptive servo-ventilation (ASV) improved cardiac sympathetic nerve function measured using 123 I-MIBG in 10 patients with central sleep apnea and HF 45 . To our knowledge, however, the current study is the first to evaluate the effects of CPAP therapy on myocardial SN function using a randomized design, quantified using 11 C-HED PET and concurrently with the evaluation post-hoc analysis definitive conclusions cannot be made. The findings support th th he e ne n n ed ed ed f f for or or further study. Of note, the magnitude of HED retention improvement with CPAP therapy in the current study was greater than the test-retest SD reported previously, albeit in different patient populations 48, 49 . Our finding are consistent with improvement in sympathetic nerve function following CPAP therapy. Whether this translates into meaningful clinical outcome benefit requires further investigation and was not within the scope of the current study. To our knowledge there are no studies to-date linking changes in HED retention to clinical outcomes.
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However, this question may be answered in ongoing RCTs.
It is noteworthy that the interaction analysis between CPAP and OSA severity with changes in 11 C-HED retention was not significant, indicating that CPAP's beneficial effects on SN function does not depend on OSA severity. Whether this represents an independent benefit of CPAP in HF requires further study.
Study Limitations
The sample size may have limited the ability to detect a significant difference in energetics isk of sudden death in patients with LV dysfunction 28 .
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We did not perform follow-up sleep studies to evaluate the efficacy of CPAP. If CPAP did not uniformly abolish OSA, such heterogeneity may have limited our ability to detect the full range of responses to effective CPAP therapy 39 .
Likewise, we were not able to determine relationships between reductions in OSA with changes in WMI or SN function. However, when we evaluated patients for whom we had objective evidence (via automated measurements) of CPAP compliance, we observed that there was a relationship between the baseline severity of OSA and the change in WMI. (This is supported by our findings that patients with worse OSA derive energetics benefit from CPAP therapy). For the same compliant group, there was no significant relationship with changes in HED retention. This may suggest the benefit of CPAP on SN function may be independent of OSA severity and relate to other mechanisms. However, without interval efficacy studies, these results must be interpreted with caution. Definitive conclusions would require additional studies that were not part of this project, but should be considered in the future.
The current study focused on patients with concomitant OSA and HFrEF. Whether CPAP might impart such benefits to patients with HFrEF without OSA merits consideration in future studies.
Therapeutic Implications and Conclusions
The most effective therapies in HF have two common features, namely they improve cardiac changes in WMI or SN function. However, when we evaluated patients for who om m m we we w h h had ad ad objective evidence (via automated measurements) of CPAP compliance, we observed that there wa was s s a a r re rela la lati ti tion on nsh hip ip ip b between the baseline severity y y o o of f OSA and the ch ch c an nge ge ge i in WMI. (This is u upp p pported by o our ur r f f fin indi di ding g gs s th th that at at p pat at tie ie ien nt n s s s w w with h w w worse e e O OSA A A de der ri r v ve ve e e ene erg rget et tic cs s be be en ne nefi fit t t fr from om om C C CPA PA PAP P h her er erap ap apy) y) y). . F F For o or t the he e s s sam am me e co co c mp mp pli lian an ant t t gr g grou ou up, p, t t the he here e e wa wa was no no o sig ig ign ni nifi i ica ca c n n nt r r rel el elat at tio ions ns n hi hi hip p p wi wi w th th th c cha ha ang ng ges es in n HED retentio on. n. n Th Th This is i m m may ay a s s sug ug ugge ge est st st t the he h b b ben en enef ef efit it t o o of f C C CPA PA PAP P on on on S S SN N N fu fu func nc ncti ti tion on on m m may ay ay b be e e in in inde de depe pe pendent of f f performance without increasing oxygen consumption and second, they favorably affect neurohormonal activation 11, 42 . The findings of this study indicate that overall, short term CPAP therapy in patients with HFrEF and OSA increases 11 C-HED retention, reflecting improved SN function, but does not appear to affect myocardial energetics in this cohort. Provocative findings from post-hoc subgroup analysis may suggest an energetics benefit for HF patients with more significant OSA, but this needs further study. Larger, outcome-based randomized trials are also warranted and are underway. *reported as median (IQR) based on N=20 in CPAP and N=22 in nonCPAP; ** for each parameter in table 2,3,5 the first p value was generated using a repeated measures growth curve mixed model by comparing the effect of CPAP from baseline to follow-up between two groups; the second p value was generated using Wilcoxon rank-sum test by comparing the delta between two groups. Figure   2A shows the Box Whisker plot of non-significant changes in K mono and WMI with short-term CPAP therapy in patients with HF and OSA; Figure 2B shows the non-significant changes in K mono and significant increase in WMI with short-term CPAP therapy in patients with HF and more severe OSA, AHI >20; *p <0.05. 
